American journal of nephrology · 2025
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mc Causland Finnian R, Claggett Brian L, Jarolim Petr, McGrath Martina M, Burdmann Emmanuel A, Eckardt Kai-Uwe, Levey Andrew S, McMurray John J V, Remuzzi Giuseppe, Singh Ajay K, Solomon Scott D, Toto Robert D, Pfeffer Marc A
Аннотация
INTRODUCTION: Endothelin-1 (ET-1) is a potent vasoconstrictor and is implicated in the pathogenesis of proteinuria and progressive chronic kidney disease (CKD). With the development of ET-1 receptor antagonists, there is interest in whether higher ET-1 concentrations are associated with a greater risk of adverse cardio-kidney events among high-risk patients, e.g., those with established CKD and type 2 diabetes mellitus (T2DM).
METHODS: ET-1 concentrations were measured in a random subset of TREAT (n = 997 [25%] of the original 4,038 patients with CKD, T2DM, and anemia) using an automated ELISA assay on the Ella analyzer (ProteinSimple). We used unadjusted and adjusted Cox regression models to explore the association of baseline serum ET-1 (log-transformed and quartiles) with kidney events (composite of kidney failure or doubling of serum creatinine), heart failure (HF), and cardiovascular and all-cause death.
RESULTS: At baseline, mean age was 67 ± 10 years and 56% were female. The mean eGFR was 34 ± 11 mL/min/1.73 m2; median urine protein/creatinine ratio was 0.4 (0.1, 1.7) g/g; median ET-1 was 2.4 (1.9, 3.0) pg/mL. During a median follow-up of 2.4 years, there were 225 kidney events, 99 HF events, 124 cardiovascular deaths, and 188 all-cause deaths. Each log-unit higher ET-1 was associated with a higher adjusted risk of the kidney composite (HR: 1.61; 95% CI: 1.08, 2.39), HF (HR: 2.61; 95% CI: 1.42, 4.81), but not with cardiovascular death (HR: 1.06; 95% CI: 0.65, 1.75) or all-cause death (HR: 1.33; 95% CI: 0.86, 2.04). Compared with the lowest quartile, categorical analyses suggested a higher risk of kidney events (HR 1.69; 95% CI 1.08, 2.64), HF events (HR: 2.35; 95% CI: 1.16, 4.80), and all-cause death (HR: 1.81; 95% CI: 1.09, 3.00) for the highest quartile of ET-1.
CONCLUSIONS: Among patients with established CKD, T2DM, and anemia, higher baseline ET-1 was associated with a higher subsequent risk of kidney outcomes, HF events, and all-cause death. Whether higher ET-1 predicts responsiveness to ET receptor antagonism warrants further investigation.
METHODS: ET-1 concentrations were measured in a random subset of TREAT (n = 997 [25%] of the original 4,038 patients with CKD, T2DM, and anemia) using an automated ELISA assay on the Ella analyzer (ProteinSimple). We used unadjusted and adjusted Cox regression models to explore the association of baseline serum ET-1 (log-transformed and quartiles) with kidney events (composite of kidney failure or doubling of serum creatinine), heart failure (HF), and cardiovascular and all-cause death.
RESULTS: At baseline, mean age was 67 ± 10 years and 56% were female. The mean eGFR was 34 ± 11 mL/min/1.73 m2; median urine protein/creatinine ratio was 0.4 (0.1, 1.7) g/g; median ET-1 was 2.4 (1.9, 3.0) pg/mL. During a median follow-up of 2.4 years, there were 225 kidney events, 99 HF events, 124 cardiovascular deaths, and 188 all-cause deaths. Each log-unit higher ET-1 was associated with a higher adjusted risk of the kidney composite (HR: 1.61; 95% CI: 1.08, 2.39), HF (HR: 2.61; 95% CI: 1.42, 4.81), but not with cardiovascular death (HR: 1.06; 95% CI: 0.65, 1.75) or all-cause death (HR: 1.33; 95% CI: 0.86, 2.04). Compared with the lowest quartile, categorical analyses suggested a higher risk of kidney events (HR 1.69; 95% CI 1.08, 2.64), HF events (HR: 2.35; 95% CI: 1.16, 4.80), and all-cause death (HR: 1.81; 95% CI: 1.09, 3.00) for the highest quartile of ET-1.
CONCLUSIONS: Among patients with established CKD, T2DM, and anemia, higher baseline ET-1 was associated with a higher subsequent risk of kidney outcomes, HF events, and all-cause death. Whether higher ET-1 predicts responsiveness to ET receptor antagonism warrants further investigation.